Zentalis Pharmaceuticals, Inc. (ZNTL)

Import this data to Google Sheets with:

=jivedata("ZNTL","financials")

Full statements spill as a table. For one cell: =jivedata("ZNTL","Revenue") or =jivedata("ZNTL","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Zentalis Pharmaceuticals, Inc.

ZNTL • CIK 0001725160

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	—	$67,425	$0	$0
Operating Income (Loss)	$-299,509	$-191,194	$-152,808	$-153,373
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$-276,892	$-165,690	$-136,618	$-136,618
Income Tax Expense (Benefit)	$-601	$177	$442	$700
Income (Loss) from Equity Method Investments	$-16,014	$0	$0	$0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-292,305	$-165,867	$-137,060	$-137,060
Net Income (Loss) Attributable to Noncontrolling Interest	$-114	$-28	$0	$0
Net Income (Loss) Attributable to Parent	$-292,191	$-165,839	$-137,060	$-139,545
Weighted Average Number of Shares Outstanding, Basic	65,409,000	71,080,000	71,869,000	70,831,000
Research and Development Expense	$189,590	$167,768	$107,295	$116,317
General and Administrative Expense	$64,351	$87,115	$37,717	$37,056
Restructuring Charges	—	—	$7,796	$0
Goodwill, Impairment Loss	$0	$3,736	$0	$0
Operating Expenses	$299,509	$258,619	$152,808	$153,373

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$28,038	$33,901	$35,995	$24,783
Debt Securities, Available-for-sale, Current	—	$318,009	$209,898	$149,825
Property, Plant and Equipment, Net	$5,819	$4,699	$2,770	$2,500
Equity Securities, FV-NI	—	$19,174	$0	$0
Operating Lease, Right-of-Use Asset	$35,916	$32,528	$26,271	$24,795
Accounts Receivable, after Allowance for Credit Loss, Current	—	$5,000	$0	$0
Prepaid Expense and Other Assets, Noncurrent	$6,818	$4,417	$4,108	$4,129
Prepaid Expense and Other Assets, Current	$13,799	$9,982	$7,298	$6,671
Restricted Cash, Noncurrent	$2,681	$2,627	$2,627	$2,627
Assets, Current	$496,718	$386,066	$253,191	$181,279
Assets	$551,688	$430,337	$288,967	$215,330
Operating Lease, Liability, Noncurrent	$43,150	$39,577	$35,704	$33,558
Other Liabilities, Noncurrent	$1,780	$849	$500	$500
Liabilities	$114,297	$93,151	$72,763	$71,684
Accounts Payable, Current	$14,926	$7,438	$7,208	$8,142
Accrued Liabilities, Current	$54,441	$45,287	$29,351	$29,484
Liabilities, Current	$69,367	$52,725	$36,559	$37,626
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$70	$71	$69	$72
Additional Paid in Capital	$1,323,576	$1,390,952	$1,407,394	$1,412,745
Accumulated Other Comprehensive Income (Loss), Net of Tax	$2,194	$558	$196	$-78
Retained Earnings (Accumulated Deficit)	$-888,556	$-1,054,395	$-1,191,455	$-1,269,093
Stockholders' Equity Attributable to Parent	$437,284	$337,186	$216,204	$143,646
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000	250,000,000	250,000,000
Common Stock, Shares, Issued	70,765,554	71,282,400	69,085,980	71,668,568

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-292,305	$-165,867	$-137,060	$-137,060
Net Cash Provided by (Used in) Operating Activities	$-207,822	$-170,860	$-125,247	$-128,095
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-14,977	$5,809	$2,094	$-12,816
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$30,719	$36,528	$38,622	$28,623
Depreciation, Depletion and Amortization	$1,389	$1,289	$739	$621
Payments to Acquire Debt Securities, Available-for-sale	$549,182	$127,962	$139,488	$139,700
Other Asset Impairment Charges	—	—	$4,136	$4,136
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	$505,307	$271,200	$250,000	$240,000
ProceedsFromSaleOfEquitySecuritiesFvNi	—	$33,479	$20,413	$20,413
Share-based Payment Arrangement, Noncash Expense	$54,822	$67,269	$20,722	$14,362
Proceeds from Sale of Property, Plant, and Equipment	—	$65	$698	$129
Goodwill, Impairment Loss	$0	$3,736	$0	$0
Payments to Acquire Property, Plant, and Equipment	$583	$221	$0	$34
Gain (Loss) on Disposition of Property Plant Equipment	$-406	$13	$660	$129
Net Cash Provided by (Used in) Investing Activities	$-44,458	$176,561	$131,623	$120,808
Equity Securities, FV-NI, Gain (Loss)	—	$5,228	$1,239	$3,622
Accretion (Amortization) of Discounts and Premiums, Investments	$13,157	$8,002	$2,763	$1,221
Income (Loss) from Equity Method Investments	$-16,014	$0	$0	$0
Deferred Income Taxes and Tax Credits	$-853	$0	$0	$0
Deconsolidation, Gain (Loss), Amount	$0	$79	$0	$0
Proceeds from Issuance of Common Stock	$235,680	$0	$5,390	$5,390
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	$1,623	$349	$304	$511
Payments for Repurchase of Common Stock	—	—	$9,976	$9,976
Net Cash Provided by (Used in) Financing Activities	$237,303	$108	$-4,282	$-5,529
Income Taxes Paid	$140	$359	$85	$85
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$602	$0	$0	$0
Cash and Cash Equivalents, at Carrying Value	$28,038	$33,901	$35,995	$25,996
Restricted Cash, Noncurrent	$2,681	$2,627	$2,627	$2,627
Increase (Decrease) in Accounts Receivable	—	$5,000	$-5,000	$-5,000
Increase (Decrease) in Prepaid Expense and Other Assets	$5,678	$-6,218	$-2,993	$-587
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$10,919	$-18,022	$-17,316	$-1,901

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("ZNTL","financials")

Full statements spill as a table. For one cell: =jivedata("ZNTL","Revenue") or =jivedata("ZNTL","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.